Ondine Biomedical and Mölnlycke Health Care have announced a strategic partnership to bring Ondine’s Steriwave nasal decolonisation technology to the United Kingdom, EU, and Middle East markets.
Steriwave, a non-antibiotic, light-activated nasal decolonisation therapy, has been clinically proven to reduce harmful pathogens in the nasal passages, a common source of healthcare-associated infections (HCAIs).
Mölnlycke’s established distribution networks, strong brand and market presence in over 100 countries make it an ideal partner to accelerate the adoption of Steriwave.
The first market focus, starting later this year, is the pivotal UK market where Steriwave has already deployed the technology into several National Health Service (NHS) Trusts, including, Mid Yorkshire Teaching NHS Trust and Leeds Teaching Hospital NHS Trust. Steriwave is also listed with NHS Supply Chain.
Mölnlycke will incorporate Steriwave as a key product in its infection control portfolio, enhancing its product offerings, with a focus on preventing HCAIs and reducing AMR.
Distribution will commence in the UK in Q4 2024, followed by expansion into the EU and Middle East regions in 2025, leveraging Mölnlycke’s extensive market presence to ultimately broaden the impact of this innovative technology on a global scale. Mölnlycke will spearhead sales and marketing efforts across the UK, EU, and Middle East.
Lina Karlsson, Executive Vice President Antiseptics, Mölnlycke, stated: "We believe that Steriwave can improve the lives of millions of people, fitting perfectly with our purpose and mission. The ability to rapidly eliminate multiple drug-resistant pathogens without generating antimicrobial resistance is key to our sustainability initiative, and complements our Hibiwash brand skin prep line, enabling us to provide comprehensive ‘nose-to-toes’ decolonisation prior to surgery.
"Universal decolonisation is now a well-accepted practice to improve surgical outcomes and produce significant cost savings to healthcare systems.”
Carolyn Cross, CEO of Ondine Biomedical, commented: “We are excited to be partnering with Mölnlycke Health Care, whose global reach, corporate vision and commitment to sustainable healthcare aligns perfectly with our own core values, purpose and mission.
"The Mölnlycke collaboration represents a transformative step towards our ambitious plans to combat HCAIs and antimicrobial resistance globally. We look forward to working with Mölnlycke in these initial key markets and beyond.”
Steriwave uses a patented light-activated agent to rapidly eliminate infection-causing pathogens in a single, 5-minute treatment. The process works so rapidly that pathogens do not have the opportunity to develop resistance, making it an effective alternative to antibiotics.
Hospitals using Steriwave have reported high levels of staff and patient compliance. Steriwave has also been proven to be highly effective against drug-resistant pathogens. A 2023 study showed that Steriwave is highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) pathogens.
